Firma ImmunOs Therapeutics, Autor bei News-Research

ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering

17. Oktober 2022 Firma ImmunOs TherapeuticsPosted in Forschung und EntwicklungTagged antibody, cancer, clinical, discovery, hla, immunos, immunotherapies, lab, new, protein, research, scil, therapy, treatment, with

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar […]

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

4. Oktober 20224. Oktober 2022 Firma ImmunOs TherapeuticsPosted in Forschung und EntwicklungTagged cancer, cedars, clinical, discovery, hla, immunos, kras, leveque, los, mba, merck, onyx, serono, therapy, with

ImmunOs Therapeutics schließt Serie B Finanzierung in Höhe von US $74 Millionen ab

7. Juni 2022 Firma ImmunOs TherapeuticsPosted in Forschung und EntwicklungTagged biomed, capital, financial, fiscus, gimv, hla, immunos, lightspeed, milla, novartis, patienten, samsara, serie, studie, therapeutics

. – Samsara, Lightspeed, Gimv und Mission BioCapital stärken als neue Anteilseigner das Investorenkonsortium und erweitern die transatlantische Präsenz – Unternehmen gründet US-Niederlassung zum Ausbau der internationalen Geschäftstätigkeit ImmunOs Therapeutics […]

ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

13. Oktober 202113. Oktober 2021 Firma ImmunOs TherapeuticsPosted in Gesundheit & MedizinTagged amp, bio, cancer, company, convention, immune, immunos, immunotherapies, immunotherapy, innate, new, swiss, therapeutics, treatment, with

ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific […]

ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases

12. April 202111. Mai 2021 Firma ImmunOs TherapeuticsPosted in Gesundheit & MedizinTagged bio, cancer, discovery, eurostars, hla, immunotherapies, mab, patients, psoriasis, sas, strong, swiss, tcr, umc, with

– ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding […]